Kintor Pharmaceutical

Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China

Kintor Pharma’s KX-826 and GT20029 for Treatment of Androgenetic Alopecia (AGA) and Acne Presented at AAD 2023

Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use

Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented

Kintor Pharma Announces Brazil’s ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Androgenetic Alopecia Was Met

GT20029’s Successful Dosing of First Batch of Subjects in China

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Proxalutamide’s Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

Kintor’s Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Re-sults in Treatment of Male and Female Patients

Kintor Proxalutamide’s COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates